Panagora Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Panagora Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.96M	Buy	324,658 +10,958	+3%	+$177K	0.02%	426
2026 Q1	$6.14M	Sell	313,700 -11,046	-3%	-$328K	0.02%	381
2025 Q4	$10.1M	Sell	324,746 -52,965	-14%	-$1.45M	0.04%	292
2025 Q3	$8.15M	Buy	377,711 +25,859	+7%	+$466K	0.03%	298
2025 Q2	$4.92M	Sell	351,852 -2,887	-0.8%	-$39.2K	0.02%	336
2025 Q1	$4.78M	Buy	354,739 +101,717	+40%	+$1.73M	0.02%	345
2024 Q4	$4.85M	Buy	253,022 +84,589	+50%	+$1.84M	0.02%	346
2024 Q3	$3.83M	Buy	+168,433	New	+$2.75M	0.02%	395
2020 Q3	–	Sell	-151	Closed	-$3K	–	2764
2020 Q2	$3K	Hold	151	–	–	﹤0.01%	2447
2020 Q1	$1K	Hold	151	–	–	﹤0.01%	2456
2019 Q4	$1K	Hold	151	–	–	﹤0.01%	2416
2019 Q3	$2K	Buy	+151	New	+$3.34K	﹤0.01%	2377
2018 Q3	–	Sell	-383	Closed	-$37K	–	2470
2018 Q2	$37K	Sell	383 -212	-36%	-$22.4K	﹤0.01%	2097
2018 Q1	$63K	Hold	595	–	–	﹤0.01%	1967
2017 Q4	$93K	Sell	595 -16	-3%	-$2.04K	﹤0.01%	1899
2017 Q3	$84K	Sell	611 -153	-20%	-$25.7K	﹤0.01%	1930
2017 Q2	$148K	Buy	764 +743	+3,538%	+$125K	﹤0.01%	1760
2017 Q1	$4K	Buy	+21	New	+$3.62K	﹤0.01%	2314

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Panagora Asset Management's VRDN Position: Q2 2026 in Review

Panagora Asset Management increased its Viridian Therapeutics (VRDN) stake by 3.5% in Q2 2026, buying an estimated $177K and bringing the position to 324,658 shares worth $5.96M. The position accounts for 0.02% of the portfolio, ranked #426.

Panagora Asset Management first reported a position in VRDN in Q1 2017 and has held it in 18 quarters since. The position peaked at $10.1M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Panagora Asset Management held 324,658 shares of Viridian Therapeutics worth $5.96M as of Q2 2026.
Panagora Asset Management bought 10,958 Viridian Therapeutics shares in Q2 2026, an estimated $177K.
Viridian Therapeutics made up 0.02% of Panagora Asset Management's portfolio in Q2 2026, its #426 holding.
Panagora Asset Management first reported a position in Viridian Therapeutics in Q1 2017 and has held it in 18 quarters since.
Panagora Asset Management's Viridian Therapeutics position peaked at $10.1M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.